Invasive Aspergillosis

Marr KA, Carter RA, Boeckh M, et al. Invasive aspergillosis in allogeneic stem cell transplant recipients: changes in epidemiology and risk factors. Blood 2002 Dec 15; 100(13): 4358–66 Kontoyiannis DP, Lionakis MS, Lewis RE, et al. Zygomycosis in a tertiary-care cancer center in the era of Aspergillus-active antifungal therapy: a case-control observational study of 27 recent cases. J Infect Dis 2005 Apr 15; 191(8): 1350–9 Cornely OA, Maertens J, Winston DJ, et al. Posaconazole vs. fluconazole or itraconazole prophylaxis in patients with neutropenia. N Engl J Med 2007 Jan 25; 356(4): 348–59 Winston DJ, Maziarz RT, Chandrasekar PH, et al. Intravenous and oral itraconazole versus intravenous and oral fluconazole for long-term antifungal prophylaxis in allogeneic hematopoietic stem-cell transplant recipients: a multicenter, randomized trial. Ann Intern Med 2003 May 6; 138(9): 705–13 Patterson TF, Kirkpatrick WR, White M, et al. Invasive aspergillosis. Disease spectrum, treatment practices, and outcomes. 13 Aspergillus Study Group. Medicine (Baltimore). 2000 Jul; 79(4): 250–60 Denning DW. Invasive aspergillosis. Clin Inf Dis 1998; 26(4): 781–805 Schwartz S, Ruhnke M, Ribaud P, et al. Improved outcome in central nervous system aspergillosis, using voriconazole treatment. Blood 2005 Oct 15; 106(8): 2641–5 Lin SJ, Schranz J, Teutsch SM. Aspergillosis case-fatality rate: systematic review of the literature. Clin Infect Dis 2001 Feb 1; 32(3): 358–66 Marr KA, Carter RA, Crippa F, et al. Epidemiology and outcome of mould infections in hematopoietic stem cell transplant recipients. Clin Infect Dis 2002 Apr 1; 34(7): 909–17 Sutton DA, Fothergill AW, Rinaldi MG. Aspergillus in vitro antifungal susceptibility data: new millennium trends. Advances Against Aspergillosis; 2004 September 9–11; San Francisco (CA): 16 Chamilos G, Luna M, Lewis RE, et al. Invasive fungal infections in patients with hematologic malignancies in a tertiary care cancer center: an autopsy study over a 15-year period (1989–2003). Haematologica 2006 Jul; 91(7): 986–9 Subira M, Martino R, Rovira M, et al. Clinical applicability of the new EORTC/MSG classification for invasive pulmonary aspergillosis in patients with hematological malignancies and autopsy-confirmed invasive aspergillosis. Ann Hematol 2003 Feb; 82(2): 80–2 Gerson SL, Talbot GH, Lusk E, et al. Invasive pulmonary aspergillosis in adult acute leukemia: clinical clues to its diagnosis. J Clin Oncol 1985 Aug; 3(8): 1109–16 Ascioglu S, Rex JH, de Pauw B, et al. Defining opportunistic invasive fungal infections in immunocompromised patients with cancer and hematopoietic stem cell transplants: an international consensus. Clin Infect Dis 2002 Jan 1; 34(1): 7–14 Groll A, Renz S, Gerein V, et al. Fatal haemoptysis associated with invasive pulmonary aspergillosis treated with high-dose amphotericin B and granulocyte-macrophage colony-stimulating factor (GM-CSF). Mycoses 1992 Mar–Apr; 35(3–4): 67–75 Boon AP, O’Brien D, Adams DH. 10 year review of invasive aspergillosis detected at necropsy. J Clin Pathol 1991 Jun; 44(6): 452–4 Yamazaki T, Kume H, Murase S, et al. Epidemiology of visceral mycoses: analysis of data in annual of the pathological autopsy cases in Japan. J Clin Microbiol 1999 Jun; 37(6): 1732–8 Vogeser M, Haas A, Aust D, et al. Postmortem analysis of invasive aspergillosis in a tertiary care hospital. Eur J Clin Microbiol Infect Dis 1997 Jan; 16(1): 1–6 Aisner J, Wiernik PH, Schimpff SC. Treatment of invasive aspergillosis: relation of early diagnosis and treatment to response. Ann Intern Med 1977 May; 86(5): 539–43 von Eiff M, Roos N, Schulten R, et al. Pulmonary aspergillosis: early diagnosis improves survival. Respiration. 1995; 62(6): 341–7 Chamilos G, Kontoyiannis DP. Defining the diagnosis of invasive aspergillosis. Med Mycol 2006 Sep; 44 Suppl.: 163–72 Bowden R, Chandrasekar P, White MH, et al. A double-blind, randomized, controlled trial of amphotericin B colloidal dispersion versus amphotericin B for treatment of invasive aspergillosis in immunocompromised patients. Clin Infect Dis 2002 Aug 15; 35(4): 359–66 Herbrecht R, Denning DW, Patterson TF, et al. Voriconazole versus amphotericin B for primary therapy of invasive aspergillosis. N Engl J Med 2002 Aug 8; 347(6): 408–15 Martino R, Subira M, Rovira M, et al. Invasive fungal infections after allogeneic peripheral blood stem cell transplantation: incidence and risk factors in 395 patients. Br J Haematol 2002 Feb; 116(2): 475–82 Cornet M, Fleury L, Maslo C, et al. Epidemiology of invasive aspergillosis in France: a six-year multicentric survey in the Greater Paris area. J Hosp Infect 2002 Aug; 51(4): 288–96 Singh N. Antifungal prophylaxis for solid organ transplant recipients: seeking clarity amidst controversy. Clin Infect Dis 2000 Aug; 31(2): 545–53 Husain S, Alexander BD, Munoz P, et al. Opportunistic mycelial fungal infections in organ transplant recipients: emerging importance of non-Aspergillus mycelial fungi. Clin Infect Dis 2003 Jul 15; 37(2): 221–9 Tumbarello M, Tacconelli E, Pagano L, et al. Comparative analysis of prognostic indicators of aspergillosis in haematological malignancies and HIV infection. J Infect 1997 Jan; 34(1): 55–60 Vandewoude K, Blot S, Depuydt P, et al. Clinical relevance of Aspergillus isolation from respiratory tract samples in critically ill patients. Crit Care 2006 Feb 17; 10(1): R31 Oren I, Haddad N, Finkelstein R, et al. Invasive pulmonary aspergillosis in neutropenic patients during hospital construction: before and after chemoprophylaxis and institution of HEPA filters. Am J Hematol 2001; 66(4): 257–62 Marr KA, Crippa F, Leisenring W, et al. Itraconazole versus fluconazole for prevention of fungal infections in patients receiving allogeneic stem cell transplants. Blood 2004 Feb 15; 103(4): 1527–33 Ribaud P, Chastang C, Latge JP, et al. Survival and prognostic factors of invasive aspergillosis after allogeneic bone marrow transplantation. Clin Infect Dis 1999 Feb; 28(2): 322–30 Cordonnier C, Ribaud P, Herbrecht R, et al. Prognostic factors for death due to invasive aspergillosis after hematopoietic stem cell transplantation: a 1-year retrospective study of consecutive patients at French transplantation centers. Clin Infect Dis 2006 Apr 1; 42(7): 955–63 Kruger W, Russmann B, Kroger N, et al. Early infections in patients undergoing bone marrow or blood stem cell transplantation: a 7 year single centre investigation of 409 cases. Bone Marrow Transplant 1999 Mar; 23(6): 589–97 Reich G, Mapara MY, Reichardt P, et al. Infectious complications after high-dose chemotherapy and autologous stem cell transplantation: comparison between patients with lymphoma or multiple myeloma and patients with solid tumors. Bone Marrow Transplant 2001; 27(5): 525–9 Salazar R, Sola C, Maroto P, et al. Infectious complications in 126 patients treated with high-dose chemotherapy and autologous peripheral blood stem cell transplantation. Bone Marrow Transplant 1999 Jan; 23(1): 27–33 Nosanchuk JD, Sepkowitz KA, Pearse RN, et al. Infectious complications of autologous bone marrow and peripheral stem cell transplantation for refractory leukemia and lymphoma. Bone Marrow Transplant 1996 Aug; 18(2): 355–9 Sevilla J, Hernandez-Maraver D, Aguado MJ, et al. Autologous peripheral blood stem cell transplant in patients previously diagnosed with invasive aspergillosis. Ann Hematol 2001 Aug; 80(8): 456–9 Michailov G, Laporte JP, Lesage S, et al. Autologous bone marrow transplantation is feasible in patients with a prior history of invasive pulmonary aspergillosis. Bone Marrow Transplant 1996 Apr; 17(4): 569–72 Fishman JA. Summary: future directions in antifungal therapy. Transpl Infect Dis 2002; 4 Suppl. 3: 67–8 Patterson JE. Epidemiology of fungal infections in solid organ transplant patients. Transpl Infect Dis 1999 Dec; 1(4): 229–36 Singh N. Impact of current transplantation practices on the changing epidemiology of infections in transplant recipients. Lancet Infect Dis 2003 Mar; 3(3): 156–61 Lortholary O, Meyohas MC, Dupont B, et al. Invasive aspergillosis in patients with acquired immunodeficiency syndrome: report of 33 cases. French Cooperative Study Group on Aspergillosis in AIDS. Am J Med 1993 Aug; 95(2): 177–87 Becker WK, Cioffi WG Jr, McManus AT, et al. Fungal burn wound infection: a 10-year experience. Arch Surg 1991 Jan; 126(1): 44–8 Stone HH, Cuzzell JZ, Kolb LD, et al. Aspergillus infection of the burn wound. J Trauma 1979 Oct; 19(10): 765–7 Bruck HM, Nash G, Foley D, et al. Opportunistic fungal infection of the burn wound with phycomycetes and Aspergillus. A clinical-pathologic review. Arch Surg 1971 May; 102(5): 476–82 Pruitt BA, MacManus AT, Kim SH, et al. Burn wound infections: current status. World J Surg 1998 Feb; 22(2): 135–45 Mousa HA. Fungal infection of burn wounds in patients with open and occlusive treatment methods. East Mediterr Health J 1999 Mar; 5(2): 333–6 Thursky KA, Worth LJ, Seymour JF, et al. Spectrum of infection, risk and recommendations for prophylaxis and screening among patients with lymphoproliferative disorders treated with alemtuzumab*. Br J Haematol 2006 Jan; 132(1): 3–12 Keating MJ, Flinn I, Jain V, et al. Therapeutic role of alemtuzumab (Campath-1H) in patients who have failed fludarabine: results of a large international study. Blood 2002 May 15; 99(10): 3554–61 Malek SK, Obmann MA, Gotoff RA, et al. Campath-1H induction and the incidence of infectious complications in adult renal transplantation. Transplantation 2006 Jan 15; 81(1): 17–20 Paterson DL, Ndirangu M, Kwak EJ, et al. Opportunistic infections in solid-organ transplant recipients pre-treated with alemtuzumab. 44th Interscience Conference on Antimicrobial Agents and Chemotherapy; 2004 Oct 30–Nov 2; Washington DC Silveira FP, Marcos A, Kwak EJ, et al. Bloodstream infections in organ transplant recipients receiving alemtuzumab: no evidence of occurrence of organisms typically associated with profound T cell depletion. J Infect 2006 Oct; 53(4): 241–7 Meersseman W, Vandecasteele SJ, Wilmer A, et al. Invasive aspergillosis in critically ill patients without malignancy. Am J Respir Crit Care Med 2004 Sep 15; 170(6): 621–5 Roosen J, Frans E, Wilmer A, et al. Comparison of premortem clinical diagnoses in critically ill patients and subsequent autopsy findings. Mayo Clin Proc 2000 Jun; 75(6): 562–7 Tai DY, El-Bilbeisi H, Tewari S, et al. A study of consecutive autopsies in a medical ICU: a comparison of clinical cause of death and autopsy diagnosis. Chest 2001 Feb; 119(2): 530–6 Gerson SL, Talbot GH, Hurwitz S, et al. Prolonged granulocytopenia: the major risk factor for invasive pulmonary aspergillosis in patients with acute leukemia. Ann Intern Med 1984 Mar; 100(3): 345–51 Muhlemann K, Wenger C, Zenhausern R, et al. Risk factors for invasive aspergillosis in neutropenic patients with hematologic malignancies. Leukemia 2005 Apr; 19(4): 545–50 Walsh TJ, Hiemenz J, Pizzo PA. Evolving risk factors for invasive fungal infections: all neutropenic patients are not the same. Clin Infect Dis 1994 May; 18(5): 793–8 Einsele H, Quabeck K, Muller KD, et al. Prediction of invasive pulmonary aspergillosis from colonisation of lower respiratory tract before marrow transplantation. Lancet 1998 Oct 31; 352(9138): 1443 Martino R, Lopez R, Sureda A, et al. Risk of reactivation of a recent invasive fungal infection in patients with hematological malignancies undergoing further intensive chemo-radiotherapy: a single-center experience and review of the literature. Haematologica 1997 May–Jun; 82(3): 297–304 Martino R, Parody R, Fukuda T, et al. Impact of the intensity of the pretransplantation conditioning regimen in patients with prior invasive aspergillosis undergoing allogeneic hematopoietic stem cell transplantation: A retrospective survey of the Infectious Diseases Working Party of the European Group for Blood and Marrow Transplantation. Blood 2006 Nov 1; 108(9): 2928–36 Einsele H, Hebart H, Kauffmann-Schneider C, et al. Risk factors for treatment failures in patients receiving PCR-based preemptive therapy for CMV infection. Bone Marrow Transplant 2000 Apr; 25(7): 757–63 Kontoyiannis DP. Why prior fluconazole use is associated with an increased risk of invasive mold infections in immunosuppressed hosts: an alternative hypothesis. Clin Infect Dis 2002 May 1; 34(9): 1281–3; author reply 3 van Burik JH, Leisenring W, Myerson D, et al. The effect of prophylactic fluconazole on the clinical spectrum of fungal diseases in bone marrow transplant recipients with special attention to hepatic candidiasis. An autopsy study of 355 patients. Medicine (Baltimore). 1998 Jul; 77(4): 246–54 Sparrelid E, Hagglund H, Remberger M, et al. Bacteraemia during the aplastic phase after allogeneic bone marrow transplantation is associated with early death from invasive fungal infection. Bone Marrow Transplant 1998 Oct; 22(8): 795–800 Singh N, Avery RK, Munoz P, et al. Trends in risk profiles for and mortality associated with invasive aspergillosis among liver transplant recipients. Clin Infect Dis. 2003 Jan 1; 36(1): 46–52 Kesh S, Mensah NY, Peterlongo P, et al. TLR1 and TLR6 polymorphisms are associated with susceptibility to invasive aspergillosis after allogeneic stem cell transplantation. Ann N Y Acad Sci. 2005 Dec; 1062: 95–103 Seo KW, Kim DH, Sohn SK, et al. Protective role of interleukin-10 promoter gene polymorphism in the pathogenesis of invasive pulmonary aspergillosis after allogeneic stem cell transplantation. Bone Marrow Transplant 2005 Dec; 36(12): 1089–95 Sainz J, Hassan L, Perez E, et al. Interleukin-10 promoter polymorphism as risk factor to develop invasive pulmonary aspergillosis. Immunol Lett 2007 Mar 15; 109(1): 76–82 Sainz J, Perez E, Hassan L, et al. Variable number of tandem repeats of TNF receptor type 2 promoter as genetic biomarker of susceptibility to develop invasive pulmonary aspergillosis. Hum Immunol 2007 Jan; 68(1): 41–50 Walsh TJ, Dixon DM. Nosocomial aspergillosis: environmental microbiology, hospital epidemiology, diagnosis and treatment. Eur J Epidemiol 1989 Jun; 5(2): 131–42 Goodley JM, Clayton YM, Hay RJ. Environmental sampling for aspergilli during building construction on a hospital site. J Hosp Infect 1994 Jan; 26(1): 27–35 Dykewicz CA. Hospital infection control in hematopoietic stem cell transplant recipients. Emerg Infect Dis 2001 Mar–Apr; 7(2): 263–7 Iwen PC, Davis JC, Reed EC, et al. Airborne fungal spore monitoring in a protective environment during hospital construction, and correlation with an outbreak of invasive aspergillosis. Infect Control Hosp Epidemiol 1994; 15(5): 303–6 Krasinski K, Holzman RS, Hanna B, et al. Nosocomial fungal infection during hospital renovation. Infect Control 1985 Jul; 6(7): 278–82 Cornet M, Levy V, Fleury L, et al. Efficacy of prevention by high-efficiency particulate air filtration or laminar airflow against Aspergillus airborne contamination during hospital renovation. Infect Control Hosp Epidemiol 1999; 20(7): 508–13 Alberti C, Bouakline A, Ribaud P, et al. Relationship between environmental fungal contamination and the incidence of invasive aspergillosis in haematology patients. J Hosp Infect 2001 Jul; 48(3): 198–206 Simmons RB, Price DL, Noble JA, et al. Fungal colonization of air filters from hospitals. Am Ind Hyg Assoc J 1997 Dec; 58(12): 900–4 Arnow PM, Sadigh M, Costas C, et al. Endemic and epidemic aspergillosis associated with in-hospital replication of Aspergillus organisms. J Infect Dis 1991 Nov; 164(5): 998–1002 Lentino JR, Rosenkranz MA, Michaels JA, et al. Nosocomial aspergillosis: a retrospective review of airborne disease secondary to road construction and contaminated air conditioners. Am J Epidemiol 1982 Sep; 116(3): 430–7 Aisner J, Schimpff SC, Bennett JE, et al. Aspergillus infections in cancer patients. Association with fireproofing materials in a new hospital. JAMA 1976 Jan 26; 235(4): 411–2 Gerson SL, Parker P, Jacobs MR, et al. Aspergillosis due to carpet contamination. Infect Control Hosp Epidemiol 1994 Apr; 15 (4 Pt 1): 221–3 Anaissie EJ, Stratton SL, Dignani MC, et al. Pathogenic Aspergillus species recovered from a hospital water system: a 3-year prospective study. Clin Infect Dis 2002 Mar 15; 34(6): 780–9 Warris A, Gaustad P, Meis JF, et al. Recovery of filamentous fungi from water in a paediatric bone marrow transplantation unit. J Hosp Infect 2001 Feb; 47(2): 143–8 Arvanitidou M, Spaia S, Velegraki A, et al. High level of recovery of fungi from water and dialysate in haemodialysis units. J Hosp Infect 2000 Jul; 45(3): 225–30 Loudon KW, Coke AP, Burnie JP, et al. Kitchens as a source of Aspergillus niger infection. J Hosp Infect 1996 Mar; 32(3): 191–8 Bouakline A, Lacroix C, Roux N, et al. Fungal contamination of food in hematology units. J Clin Microbiol 2000 Nov; 38(11): 4272–3 Hospenthal DR, Kwon-Chung KJ, Bennett JE. Concentrations of airborne Aspergillus compared to the incidence of invasive aspergillosis: lack of correlation. Med Mycol 1998 Jun; 36(3): 165–8 Anaissie EJ, Stratton SL, Dignani MC, et al. Pathogenic molds (including Aspergillus species) in hospital water distribution systems: a 3-year prospective study and clinical implications for patients with hematologic malignancies. Blood 2003 Apr 1; 101(7): 2542–6 Garber G. An overview of fungal infections. Drugs. 2001; 61 Suppl. 1: 1–12 Menotti J, Waller J, Meunier O, et al. Epidemiological study of invasive pulmonary aspergillosis in a haematology unit by molecular typing of environmental and patient isolates of Aspergillus fumigatus. J Hosp Infect 2005 May; 60(1): 61–8 Lass-Flörl C, Salzer GM, Schmid T, et al. Pulmonary Aspergillus colonization in humans and its impact on management of critically ill patients. Br J Haematol 1999 Mar; 104(4): 745–7 Sherertz RJ, Belani A, Kramer BS, et al. Impact of air filtration on nosocomial Aspergillus infections. Unique risk of bone marrow transplant recipients. Am J Med 1987 Oct; 83(4): 709–18 Heussel CP, Kauczor HU, Heussel GE, et al. Pneumonia in febrile neutropenic patients and in bone marrow and blood stem-cell transplant recipients: use of high-resolution computed tomography. J Clin Oncol 1999 Mar; 17(3): 796–805 Caillot D, Couaillier JF, Bernard A, et al. Increasing volume and changing characteristics of invasive pulmonary aspergillosis on sequential thoracic computed tomography scans in patients with neutropenia. J Clin Oncol 2001 Jan 1; 19(1): 253–9 Brodoefel H, Vogel M, Hebart H, et al. Long-term CT follow-up in 40 non-HIV immunocompromised patients with invasive pulmonary aspergillosis: kinetics of CT morphology and correlation with clinical findings and outcome. AJR Am J Roentgenol 2006 Aug; 187(2): 404–13 Greene RE, Schlamm HT, Oestmann JW, et al. Imaging findings in acute invasive pulmonary aspergillosis: clinical significance of the halo sign. Clin Infect Dis 2007 Feb 1; 44(3): 373–9 Escuissato DL, Gasparetto EL, Marchiori E, et al. Pulmonary infections after bone marrow transplantation: high-resolution CT findings in 111 patients. AJR Am J Roentgenol. 2005 Sep; 185(3): 608–15 Sonnet S, Buitrago-Tellez CH, Tamm M, et al. Direct detection of angioinvasive pulmonary aspergillosis in immunosuppressed patients: preliminary results with high-resolution 16-MDCT angiography. AJR Am J Roentgenol 2005 Mar; 184(3): 746–51 Mennink-Kersten MA, Donnelly JP, Verweij PE. Detection of circulating galactomannan for the diagnosis and management of invasive aspergillosis. Lancet Infect Dis 2004 Jun; 4(6): 349–57 Odabasi Z, Mattiuzzi G, Estey E, et al. Beta-D-glucan as a diagnostic adjunct for invasive fungal infections: validation, cutoff development, and performance in patients with acute myelogenous leukemia and myelodysplastic syndrome. Clin Infect Dis 2004 Jul 15; 39(2): 199–205 Yeo SF, Wong B. Current status of nonculture methods for diagnosis of invasive fungal infections. Clin Microbiol Rev 2002 Jul; 15(3): 465–84 Mennink-Kersten MA, Ruegebrink D, Wasei N, et al. In vitro release by Aspergillus fumigatus of galactofuranose antigens, 1,3-beta-D-glucan, and DNA, surrogate markers used for diagnosis of invasive aspergillosis. J Clin Microbiol 2006 May; 44(5): 1711–8 Odabasi Z, Paetznick VL, Rodriguez JR, et al. Differences in beta-glucan levels in culture supernatants of a variety of fungi. Med Mycol 2006 May; 44(3): 267–72 Maertens J, Verhaegen J, Lagrou K, et al. Screening for circulating galactomannan as a noninvasive diagnostic tool for invasive aspergillosis in prolonged neutropenic patients and stem cell transplantation recipients: a prospective validation. Blood 2001 Mar 15; 97(6): 1604–10 Maertens J, Van Eldere J, Verhaegen J, et al. Use of circulating galactomannan screening for early diagnosis of invasive aspergillosis in allogeneic stem cell transplant recipients. J Infect Dis 2002 Nov 1; 186(9): 1297–306 Weisser M, Rausch C, Droll A, et al. Galactomannan does not precede major signs on a pulmonary computerized tomographic scan suggestive of invasive aspergillosis in patients with hematological malignancies. Clin Infect Dis 2005 Oct 15; 41(8): 1143–9 Rovira M, Jimenez M, De La Bellacasa JP, et al. Detection of Aspergillus galactomannan by enzyme immunoabsorbent assay in recipients of allogeneic hematopoietic stem cell transplantation: a prospective study. Transplantation 2004 Apr 27; 77(8): 1260–4 Williamson EC, Oliver DA, Johnson EM, et al. Aspergillus antigen testing in bone marrow transplant recipients. J Clin Pathol 2000 May; 53(5): 362–6 Klont RR, Mennink-Kersten MA, Verweij PE. Utility of Aspergillus antigen detection in specimens other than serum specimens. Clin Infect Dis 2004 Nov 15; 39(10): 1467–74 Verweij PE, Latge JP, Rijs AJ, et al. Comparison of antigen detection and PCR assay using bronchoalveolar lavage fluid for diagnosing invasive pulmonary aspergillosis in patients receiving treatment for hematological malignancies. J Clin Microbiol 1995 Dec; 33(12): 3150–3 Salonen J, Lehtonen OP, Terasjarvi MR, et al. Aspergillus antigen in serum, urine and bronchoalveolar lavage specimens of neutropenic patients in relation to clinical outcome. Scand J Infect Dis 2000; 32(5): 485–90 Klont RR, Mennink-Kersten MA, Ruegebrink D, et al. Paradoxical increase in circulating Aspergillus antigen during treatment with caspofungin in a patient with pulmonary aspergillosis. Clin Infect Dis 2006 Aug 1; 43(3): e23–5 Maertens J, Glasmacher A, Selleslag D, et al. Evaluation of serum sandwich enzyme-linked immunosorbent assay for circulating galactomannan during caspofungin therapy: results from the caspofungin invasive aspergillosis study. Clin Infect Dis 2005 Jul 1; 41(1): e9–14 Pfeiffer CD, Fine JP, Safdar N. Diagnosis of invasive aspergillosis using a galactomannan assay: a meta-analysis. Clin Infect Dis 2006 May 15; 42(10): 1417–727 Rex JH. Galactomannan and the diagnosis of invasive aspergillosis. Clin Infect Dis 2006 May 15; 42(10): 1428–30 Herbrecht R, Letscher-Bru V, Oprea C, et al. Aspergillus galactomannan detection in the diagnosis of invasive aspergillosis in cancer patients. J Clin Oncol 2002 Apr 1; 20(7): 1898–906 Kawazu M, Kanda Y, Nannya Y, et al. Prospective comparison of the diagnostic potential of real-time PCR, double-sandwich enzyme-linked immunosorbent assay for galactomannan, and a (1>3)-beta-D-glucan test in weekly screening for invasive aspergillosis in patients with hematological disorders. J Clin Microbiol 2004 Jun; 42(6): 2733–41 Marr KA, Balajee SA, McLaughlin L, et al. Detection of galactomannan antigenemia by enzyme immunoassay for the diagnosis of invasive aspergillosis: variables that affect performance. J Infect Dis 2004 Aug 1; 190(3): 641–9 Marr KA, Laverdiere M, Gugel A, et al. Antifungal therapy decreases sensitivity of the Aspergillus galactomannan enzyme immunoassay. Clin Infect Dis 2005 Jun 15; 40(12): 1762–9 Maertens J, Theunissen K, Verbeken E, et al. Prospective clinical evaluation of lower cut-offs for galactomannan detection in adult neutropenic cancer patients and haematological stem cell transplant recipients. Br J Haematol 2004 Sep; 126(6): 852–60 Kappe R, Schulze-Berge A. New cause for false-positive results with the Pastorex Aspergillus antigen latex agglutination test. J Clin Microbiol 1993 Sep; 31(9): 2489–90 Giacchino M, Chiapello N, Riva C, et al. Intracranial aspergillosis in children successfully treated with antifungal therapy and surgical intervention. Pediatr Infect Dis J 2006 Apr; 25(4): 379–81 Mattei D, Rapezzi D, Mordini N, et al. False-positive Aspergillus galactomannan enzyme-linked immunosorbent assay results in vivo during amoxicillin-clavulanic acid treatment. J Clin Microbiol 2004 Nov; 42(11): 5362–3 Maertens J, Theunissen K, Verhoef G, et al. False-positive Aspergillus galactomannan antigen test results. Clin Infect Dis 2004 Jul 15; 39(2): 289–90 Metan G, Duruscu M, Uzun O. False positivity for Aspergillus antigenemia with amoxicillin-clavulonic acid. J Clin Microbiol 2005 May; 2548; author reply 2549 Viscoli C, Machetti M, Cappellano P, et al. False-positive galactomannan platelia Aspergillus test results for patients receiving piperacillin-tazobactam. Clin Infect Dis 2004 Mar 15; 38(6): 913–6 Sulahian A, Touratier S, Ribaud P. False positive test for Aspergillus antigenemia related to concomitant administration of piperacillin and tazobactam. N Engl J Med 2003 Dec 11; 349(24): 2366–7 Adam O, Auperin A, Wilquin F, et al. Treatment with piperacillin-tazobactam and false-positive Aspergillus galactomannan antigen test results for patients with hematological malignancies. Clin Infect Dis 2004 Mar 15; 38(6): 917–20 Link H, Böhme A, Cornely OA, et al. Antimicrobial therapy of unexplained fever in neutropenic patients. Guidelines of the Infectious Diseases Working Party (AGIHO) of the German Society of Hematology and Oncology (DGHO). Ann Hematol 2003 Oct; 82 Suppl. 2: S105–17 Aubry A, Porcher R, Bottero J, et al. Occurrence and kinetics of false-positive Aspergillus galactomannan test results following treatment with beta-lactam antibiotics in patients with hematological disorders. J Clin Microbiol 2006 Feb; 44(2): 389–94 Machetti M, Majabo MJ, Furfaro E, et al. Kinetics of galactomannan in surgical patients receiving perioperative piperacillin/tazobactam prophylaxis. J Antimicrob Chemother 2006 Oct; 58(4): 806–10 Hage CA, Reynolds JM, Durkin M, et al. Plasmalyte as a cause of false-positive results for Aspergillus galactomannan in bronchoalveolar lavage fluid. J Clin Microbiol 2007 Feb; 45(2): 676–7 Obayashi T, Yoshida M, Mori T, et al. Plasma (1>3)-beta-D-glucan measurement in diagnosis of invasive deep mycosis and fungal febrile episodes. Lancet. 1995 Jan 7; 345(8941): 17–20 Ostrosky-Zeichner L, Alexander BD, Kett DH, et al. Multicenter clinical evaluation of the (1>3) beta-D-glucan assay as an aid to diagnosis of fungal infections in humans. Clin Infect Dis 2005 Sep 1; 41(5): 654–9 Pickering JW, Sant HW, Bowles CA, et al. Evaluation of a (1>3)-beta-D-glucan assay for diagnosis of invasive fungal infections. J Clin Microbiol 2005 Dec; 43(12): 5957–62 Pazos C, Ponton J, Del Palacio A. Contribution of (l>3)-beta-D-glucan chromogenic assay to diagnosis and therapeutic monitoring of invasive aspergillosis in neutropenic adult patients: a comparison with serial screening for circulating galactomannan. J Clin Microbiol 2005 Jan; 43(1): 299–305 Mennink-Kersten MA, Warris A, Verweij PE. 1,3-beta-D-glucan in patients receiving intravenous amoxicillin-clavulanic acid. N Engl J Med 2006 Jun 29; 354(26): 2834–5 Einsele H, Hebart H, Roller G, et al. Detection and identification of fungal pathogens in blood by using molecular probes. J Clin Microbiol 1997 Jun; 35(6): 1353–60 Hebart H, Löffler J, Meisner C, et al. Early detection of Aspergillus infection after allogeneic stem cell transplantation by polymerase chain reaction screening. J Infect Dis 2000 May; 181(5): 1713–9 Buchheidt D, Hummel M, Schleiermacher D, et al. Prospective clinical evaluation of a LightCycler-mediated polymerase chain reaction assay, a nested-PCR assay and a galactomannan enzyme-linked immunosorbent assay for detection of invasive aspergillosis in neutropenic cancer patients and haematological stem cell transplant recipients. Br J Haematol 2004 Apr; 125(2): 196–202 Florent M, Katsahian S, Vekhoff A, et al. Prospective evaluation of a polymerase chain reaction-ELISA targeted to Aspergillus fumigatus and Aspergillus flavus for the early diagnosis of invasive aspergillosis in patients with hematological malignancies. J Infect Dis 2006 Mar 1; 193(5): 741–7 Millon L, Piarroux R, Deconinck E, et al. Use of real-time PCR to process the first galactomannan-positive serum sample in diagnosing invasive aspergillosis. J Clin Microbiol 2005 Oct; 43(10): 5097–101 Buchheidt D, Baust C, Skladny H, et al. Clinical evaluation of a polymerase chain reaction assay to detect Aspergillus species in bronchoalveolar lavage samples of neutropenic patients. Br J Haematol 2002 Mar; 116(4): 803–11 Hummel M, Spiess B, Kentouche K, et al. Detection of Aspergillus DNA in cerebrospinal fluid from patients with cerebral aspergillosis by a nested PCR assay. J Clin Microbiol 2006 Nov; 44(11): 3989–93 Maertens J, Theunissen K, Verhoef G, et al. Galactomannan and computed tomography-based preemptive antifungal therapy in neutropenic patients at high risk for invasive fungal infection: a prospective feasibility study. Clin Infect Dis 2005 Nov 1; 41(9): 1242–50 Zedek DC, Miller MB. Use of galactomannan enzyme immunoassay for diagnosis of invasive aspergillosis in a tertiarycare center over a 12-month period. J Clin Microbiol 2006 Apr; 44(4): 1601 White PL, Barton R, Guiver M, et al. A consensus on fungal polymerase chain reaction diagnosis? A United Kingdom-Ireland evaluation of polymerase chain reaction methods for detection of systemic fungal infections. J Mol Diagn 2006 Jul; 8(3): 376–84 Busca A, Locatelli F, Barbui A, et al. Usefulness of sequential Aspergillus galactomannan antigen detection combined with early radiologic evaluation for diagnosis of invasive pulmonary aspergillosis in patients undergoing allogeneic stem cell transplantation. Transplant Proc 2006 Jun; 38(5): 1610–3 Stevens DA, Kan VL, Judson MA, et al. Practice guidelines for diseases caused by Aspergillus. Infectious Diseases Society of America. Clin Infect Dis 2000 Apr; 30(4): 696–709 Böhme A, Ruhnke M, Buchheidt D, et al. Treatment of fungal infections in hematology and oncology: guidelines of the Infectious Diseases Working Party (AGIHO) of the German Society of Hematology and Oncology (DGHO). Ann Hematol 2003 Oct; 82 Suppl. 2: S133–40 Maschmeyer G, Beinert T, Buchheidt D, et al. Diagnosis and antimicrobial therapy of pulmonary infiltrates in febrile neutropenic patients: guidelines of the Infectious Diseases Working Party (AGIHO) of the German Society of Hematology and Oncology (DGHO). Ann Hematol 2003 Oct; 82 Suppl. 2: S118–26 Empiric antifungal therapy in febrile granulocytopenic patients. EORTC International Antimicrobial Therapy Cooperative Group. Am J Med. 1989 Jun; 86 (6 Pt 1): 668–72 Pizzo PA, Robichaud KJ, Gill FA, et al. Empiric antibiotic and antifungal therapy for cancer patients with prolonged fever and granulocytopenia. Am J Med 1982 Jan; 72(1): 101–11 Schiel X, Link H, Maschmeyer G, et al. A prospective, randomized multicenter trial of the empirical addition of antifungal therapy for febrile neutropenic cancer patients: results of the Paul Ehrlich Society for Chemotherapy (PEG) multicenter trial II. Infection 2006 Jun; 34(3): 118–26 Hughes WT, Armstrong D, Bodey GP, et al. 2002 guidelines for the use of antimicrobial agents in neutropenic patients with cancer. Clin Infect Dis 2002 Mar 15; 34(6): 730–51 Cornely OA, Maertens J, Bresnik M, et al. Liposomal amphotericin B as initial therapy for invasive filamentous fungal infections: a randomized trial comparing a high loading dose regimen with standard dosing (AmBiLoad Trial). Clin Infect Dis 2007 May 15; 44(10): 1289–97 Maschmeyer G, Haas A. Defining clinical failure for salvage studies. Med Mycol 2006 Sep; 44 Suppl.: 315–8 Lass-Florl C, Griff K, Mayr A, et al. Epidemiology and outcome of infections due to Aspergillus terreus; 10-year single centre experience. Br J Haematol 2005 Oct; 131(2): 201–7 Steinbach WJ, Benjamin DK Jr, Kontoyiannis DP, et al. Aspergillus terreus: a multicenter retrospective analysis of 83 cases. Clin Infect Dis 2004 Jul 15; 39(2): 192–8 Denning DW, Venkateswarlu K, Oakley KL, et al. Itraconazole resistance in Aspergillus fumigatus. Antimicrob Agents Chemother 1997 Jun; 41(6): 1364–8 Mellado E, Garcia-Effron G, Alcazar-Fuoli L, et al. A new Aspergillus fumigatus resistance mechanism conferring in vitro cross-resistance to azole antifungals involves a combination of cyp51A alterations. Antimicrob Agents Chemother 2007; 51(6): 1897–904 Verweij PE, Mellado E, Melchers WJ. Multiple-triazole-resistant aspergillosis. N Engl J Med 2007 Apr 5; 356(14): 1481–3 Andes D. In vivo pharmacodynamics of antifungal drugs in treatment of candidiasis. Antimicrob Agents Chemother 2003 Apr; 47(4): 1179–86 Wiederhold NP, Kontoyiannis DP, Chi J, et al. Pharmacodynamics of caspofungin in a murine model of invasive pulmonary aspergillosis: evidence of concentration-dependent activity. J Infect Dis 2004 Oct 15; 190(8): 1464–71 Ellis M, Spence D, de Pauw B, et al. An EORTC international multicenter randomized trial (EORTC number 19923) comparing two dosages of liposomal amphotericin B for treatment of invasive aspergillosis. Clin Infect Dis 1998 Dec; 27(6): 1406–12 Schwartz S, Thiel E. Update on the treatment of cerebral aspergillosis. Ann Hematol 2004; 83 Suppl. 1: S42–4 Groll AH, Gea-Banacloche JC, Glasmacher A, et al. Clinical pharmacology of antifungal compounds. Infect Dis Clin North Am 2003 Mar; 17(1): 159–91, ix Wong-Beringer A, Jacobs RA, Guglielmo BJ. Lipid formulations of amphotericin B: clinical efficacy and toxicities. Clin Infect Dis 1998 Sep; 27(3): 603–18 Balloy V, Huerre M, Latge JP, et al. Differences in patterns of infection and inflammation for corticosteroid treatment and chemotherapy in experimental invasive pulmonary aspergillosis. Infect Immun 2005 Jan; 73(1): 494–503 Paterson PJ, Seaton S, Prentice HG, et al. Treatment failure in invasive aspergillosis: susceptibility of deep tissue isolates following treatment with amphotericin B. J Antimicrob Chemother 2003 Nov; 52(5): 873–6 Patterson TF, Boucher HW, Herbrecht R, et al. Strategy of following voriconazole versus amphotericin B therapy with other licensed antifungal therapy for primary treatment of invasive aspergillosis: impact of other therapies on outcome. Clin Infect Dis 2005 Nov 15; 41(10): 1448–52 Maschmeyer G, Link H, Hiddemann W, et al. Pulmonary infiltrations in febrile patients with neutropenia. Risk factors and outcome under empirical antimicrobial therapy in a randomized multicenter study. Cancer 1994; 73(9): 2296–304 Bates DW, Su L, Yu DT, et al. Mortality and costs of acute renal failure associated with amphotericin B therapy. Clin Infect Dis 2001 Mar 1; 32(5): 686–93 Wingard JR, Kubilis P, Lee L, et al. Clinical significance of nephrotoxicity in patients treated with amphotericin B for suspected or proven aspergillosis. Clin Infect Dis 1999 Dec; 29(6): 1402–7 Ullmann AJ, Sanz MA, Tramarin A, et al. Prospective study of amphotericin B formulations in immunocompromised patients in 4 European countries. Clin Infect Dis 2006 Aug 15; 43(4): e29–38 Eriksson U, Seifert B, Schaffner A. Comparison of effects of amphotericin B deoxycholate infused over 4 or 24 hours: randomised controlled trial. BMJ 2001 Mar 10; 322(7286): 579–82 Imhof A, Walter RB, Schaffner A. Continuous infusion of escalated doses of amphotericin B deoxycholate: an open-label observational study. Clin Infect Dis 2003 Apr 15; 36(8): 943–51 Leenders AC, Daenen S, Jansen RL, et al. Liposomal amphotericin B compared with amphotericin B deoxycholate in the treatment of documented and suspected neutropenia-associated invasive fungal infections. Br J Haematol 1998 Oct; 103(1): 205–12 Walsh TJ, Finberg RW, Arndt C, et al. Liposomal amphotericin B for empirical therapy in patients with persistent fever and neutropenia. National Institute of Allergy and Infectious Diseases Mycoses Study Group. N Engl J Med 1999 Mar 11; 340(10): 764–71 Meunier F, Prentice HG, Ringden O. Liposomal amphotericin B (AmBisome): safety data from a phase II/III clinical trial. J Antimicrob Chemother 1991; 28 Suppl. B: 83–91 Prentice HG, Hann IM, Herbrecht R, et al. A randomized comparison of liposomal versus conventional amphotericin B for the treatment of pyrexia of unknown origin in neutropenic patients. Br J Haematol 1997; 98(3): 711–8 Walsh TJ, Pappas P, Winston DJ, et al. Voriconazole compared with liposomal amphotericin B for empirical antifungal therapy in patients with neutropenia and persistent fever. N Engl J Med 2002 Jan 24; 346(4): 225–34 Walsh TJ, Teppler H, Donowitz GR, et al. Caspofungin versus liposomal amphotericin B for empirical antifungal therapy in patients with persistent fever and neutropenia. N Engl J Med 2004 Sep 30; 351(14): 1391–402 Adler-Moore JP, Proffitt RT. Development, characterization, efficacy and mode of action of AmBisome, a unilamellar liposomal formulation of amphotericin B. J Liposome Res 1993; 3: 429–50 Walsh TJ, Goodman JL, Pappas P, et al. Safety, tolerance, and pharmacokinetics of high-dose liposomal amphotericin B (AmBisome) in patients infected with Aspergillus species and other filamentous fungi: maximum tolerated dose study. Antimicrob Agents Chemother 2001 Dec; 45(12): 3487–96 Janoff AS, Perkins WR, Saletan SL, et al. e. Amphotericin B lipid complex (ABLC): a molecular rationale for the attenuation of amphotericin B related toxicities. J Liposome Res 1993; 3: 451–71 Chandrasekar PH, Ito JI. Amphotericin B lipid complex in the management of invasive aspergillosis in immunocompromised patients. Clin Infect Dis 2005 May 1; 40 Suppl. 6: S392–400 Walsh TJ, Hiemenz JW, Seibel NL, et al. Amphotericin B lipid complex for invasive fungal infections: analysis of safety and efficacy in 556 cases. Clin Infect Dis 1998; 26(6): 1383–96 Martino R, Cortes M, Subira M, et al. Efficacy and toxicity of intermediate-dose amphotericin B lipid complex as a primary or salvage treatment of fungal infections in patients with hematological malignancies. Leuk Lymphoma 2005 Oct; 46(10): 1429–35 Martino R. Efficacy, safety and cost-effectiveness of Amphotericin B Lipid Complex (ABLC): a review of the literature. Curr Med Res Opin 2004 Apr; 20(4): 485–504 Miller CB, Waller EK, Klingemann HG, et al. Lipid formulations of amphotericin B preserve and stabilize renal function in HSCT recipients. Bone Marrow Transplant 2004 Mar; 33(5): 543–8 Alexander BD, Wingard JR. Study of renal safety in amphotericin B lipid complex-treated patients. Clin Infect Dis 2005 May 1; 40 Suppl. 6: S414–21 Denning DW, Ribaud P, Milpied N, et al. Efficacy and safety of voriconazole in the treatment of acute invasive aspergillosis. Clin Infect Dis 2002 Mar 1; 34(5): 563–71 Walsh TJ, Raad I, Patterson TF, et al. Treatment of invasive aspergillosis with posaconazole in patients who are refractory to or intolerant of conventional therapy: an externally controlled trial. Clin Infect Dis 2007 Jan 1; 44(1): 2–12 Wexler D, Courtney R, Richards W, et al. Effect of posaconazole on cytochrome P450 enzymes: a randomized, open-label, two-way crossover study. Eur J Pharm Sci 2004 Apr; 21(5): 645–53 Boogaerts M, Winston DJ, Bow EJ, et al. Intravenous and oral itraconazole versus intravenous amphotericin B deoxycholate as empirical antifungal therapy for persistent fever in neutropenic patients with cancer who are receiving broad-spectrum antibacterial therapy. A randomized, controlled trial. Ann Intern Med 2001 Sep 18; 135(6): 412–22 Denning DW, Tucker RM, Hanson LH, et al. Treatment of invasive aspergillosis with itraconazole. Am J Med 1989 Jun; 86 (6 Pt 2): 791–800 Denning DW, Lee JY, Hostetler JS, et al. NIAID Mycoses Study Group Multicenter Trial of Oral Itraconazole Therapy for Invasive Aspergillosis. Am J Med 1994 Aug; 97(2): 135–44 Caillot D, Bassaris H, McGeer A, et al. Intravenous itraconazole followed by oral itraconazole in the treatment of invasive pulmonary aspergillosis in patients with hematologic malignancies, chronic granulomatous disease, or AIDS. Clin Infect Dis 2001 Oct 15; 33(8): e83–90 van’t Wout JW, Novakova I, Verhagen CA, et al. The efficacy of itraconazole against systemic fungal infections in neutropenic patients: a randomised comparative study with amphotericin B. J Infect 1991 Jan; 22(1): 45–52 Glasmacher A, Hahn C, Molitor E, et al. Itraconazole through concentrations in antifungal prophylaxis with six different dosing regimens using hydroxypropyl-beta-cyclodextrin oral solution or coated-pellet capsules. Mycoses 1999; 42(11–12): 591–600 Marr KA, Leisenring W, Crippa F, et al. Cyclophosphamide metabolism is affected by azole antifungals. Blood 2004 Feb 15; 103(4): 1557–9 Ahmad SR, Singer SJ, Leissa BG. Congestive heart failure associated with itraconazole. Lancet 2001; 357(9270): 1766–7 Maertens J, Raad I, Petrikkos G, et al. Efficacy and safety of caspofungin for treatment of invasive aspergillosis in patients refractory to or intolerant of conventional antifungal therapy. Clin Infect Dis 2004 Dec 1; 39(11): 1563–71 Arikan S, Lozano-Chiu M, Paetznick V, et al. In vitro synergy of caspofungin and amphotericin B against Aspergillus and Fusarium spp. Antimicrob Agents Chemother 2002 Jan; 46(1): 245–7 Kirkpatrick WR, Perea S, Coco BJ, et al. Efficacy of caspofungin alone and in combination with voriconazole in a Guinea pig model of invasive aspergillosis. Antimicrob Agents Chemother 2002 Aug; 46(8): 2564–8 Aliff TB, Maslak PG, Jurcic JG, et al. Refractory Aspergillus pneumonia in patients with acute leukemia: successful therapy with combination caspofungin and liposomal amphotericin. Cancer 2003 Feb 15; 97(4): 1025–32 Kontoyiannis DP, Hachem R, Lewis RE, et al. Efficacy and toxicity of caspofungin in combination with liposomal amphotericin B as primary or salvage treatment of invasive aspergillosis in patients with hematologic malignancies. Cancer 2003 Jul 15; 98(2): 292–9 Marr KA, Boeckh M, Carter RA, et al. Combination antifungal therapy for invasive aspergillosis. Clin Infect Dis. 2004 Sep 15; 39(6): 797–802 Sable CA, Nguyen BY, Chodakewitz JA, et al. Safety and tolerability of caspofungin acetate in the treatment of fungal infections. Transpl Infect Dis 2002 Jun; 4(1): 25–30 Trenschel R, Ditschkowski M, Elmaagacli AH, et al. Caspofungin as second-line therapy for fever of unknown origin or invasive fungal infection following allogeneic stem cell transplantation. Bone Marrow Transplant 2005; 35(6): 583–6 Kohno S, Masaoka T, Yamaguchi H, et al. A multicenter, open-label clinical study of micafungin (FK463) in the treatment of deep-seated mycosis in Japan. Scand J Infect Dis 2004; 36(5): 372–9 Denning DW, Marr KA, Lau WM, et al. Micafungin (FK463), alone or in combination with other systemic antifungal agents, for the treatment of acute invasive aspergillosis. J Infect 2006; 53(5): 337–49 Benjamin DK Jr, Driscoll T, Seibel NL, et al. Safety and pharmacokinetics of intravenous anidulafungin in children with neutropenia at high risk for invasive fungal infections. Antimicrob Agents Chemother 2006 Feb; 50(2): 632–8 Herbrecht R, Graham D, Schuster M. Safety and tolerability of combination anidulafungin and liposomal amphotericin B for the treatment of invasive aspergillosis. Focus on Fungal Infections 14; 2004 Mar 24–26; New Orleans, LA, 2004: 11 Petraitis V, Petraitiene R, Sarafandi AA, et al. Combination therapy in treatment of experimental pulmonary aspergillosis: synergistic interaction between an antifungal triazole and an echinocandin. J Infect Dis 2003 Jun 15; 187(12): 1834–43 Steinbach WJ, Stevens DA, Denning DW. Combination and sequential antifungal therapy for invasive aspergillosis: review of published in vitro and in vivo interactions and 6281 clinical cases from 1966 to 2001. Clin Infect Dis 2003 Oct 1; 37 Suppl. 3: S188–224 Meletiadis J, Petraitis V, Petraitiene R, et al. Triazole-polyene antagonism in experimental invasive pulmonary aspergillosis: in vitro and in vivo correlation. J Infect Dis 2006 Oct 1; 194(7): 1008–18 Maertens J, Glasmacher A, Herbrecht R, et al. Multicenter, noncomparative study of caspofungin in combination with other antifungals as salvage therapy in adults with invasive aspergillosis. Cancer 2006 Dec 15; 107(12): 2888–97 Wald A, Leisenring W, van Burik JA, et al. Epidemiology of Aspergillus infections in a large cohort of patients undergoing bone marrow transplantation. J Infect Dis 1997 Jun; 175(6): 1459–66 Bodey GP, Anaissie E, Gutterman J, et al. Role of granulocyte-macrophage colony-stimulating factor as adjuvant therapy for fungal infection in patients with cancer. Clin Infect Dis 1993; 17(4): 705–7 Todeschini G, Murari C, Bonesi R, et al. Invasive aspergillosis in neutropenic patients: rapid neutrophil recovery is a risk factor for severe pulmonary complications. Eur J Clin Invest 1999 May; 29(5): 453–7 Dignani MC, Anaissie EJ, Hester JP, et al. Treatment of neutropenia-related fungal infections with granulocyte colony-stimulating factor-elicited white blood cell transfusions: a pilot study. Leukemia 1997 Oct; 11(10): 1621–30 Kerr JP, Liakopolou E, Brown J, et al. The use of stimulated granulocyte transfusions to prevent recurrence of past severe infections after allogeneic stem cell transplantation. Br J Haematol. 2003 Oct; 123(1): 114–8 Mousset S, Hermann S, Klein SA, et al. Prophylactic and interventional granulocyte transfusions in patients with haematological malignancies and life-threatening infections during neutropenia. Ann Hematol 2005 Oct; 84(11): 734–41 Matt P, Bernet F, Habicht J, et al. Predicting outcome after lung resection for invasive pulmonary aspergillosis in patients with neutropenia. Chest 2004 Dec; 126(6): 1783–8 Bernard A, Caillot D, Couaillier JF, et al. Surgical management of invasive pulmonary aspergillosis in neutropenic patients. Ann Thorac Surg 1997 Nov; 64(5): 1441–7 Yeghen T, Kibbler CC, Prentice HG, et al. Management of invasive pulmonary aspergillosis in hematology patients: a review of 87 consecutive cases at a single institution. Clin Infect Dis 2000 Oct; 31(4): 859–68 Cornely OA, Ullmann AJ, Karthaus M. Evidence-based assessment of primary antifungal prophylaxis in patients with hematologic malignancies. Blood 2003 May 1; 101(9): 3365–72 Cornely OA, Böhme A, Buchheidt D, et al. Prophylaxis of invasive fungal infections in patients with hematological malignancies and solid tumors. Guidelines of the Infectious Diseases Working Party (AGIHO) of the German Society of Hematology and Oncology (DGHO). Ann Hematol. 2003 Oct; 82 Suppl. 2: S186–200 Glasmacher A, Prentice A, Gorschluter M, et al. Itraconazole prevents invasive fungal infections in neutropenic patients treated for hematologic malignancies: evidence from a meta-analysis of 3,597 patients. J Clin Oncol 2003 Dec 15; 21(24): 4615–26 Vardakas KZ, Michalopoulos A, Falagas ME. Fluconazole versus itraconazole for antifungal prophylaxis in neutropenic patients with haematological malignancies: a meta-analysis of randomised-controlled trials. Br J Haematol 2005 Oct; 131(1): 22–8 Bow EJ, Laverdiere M, Lussier N, et al. Antifungal prophylaxis for severely neutropenic chemotherapy recipients: a meta analysis of randomized-controlled clinical trials. Cancer 2002 Jun 15; 94(12): 3230–46 Kanda Y, Yamamoto R, Chizuka A, et al. Prophylactic action of oral fluconazole against fungal infection in neutropenic patients. A meta-analysis of 16 randomized, controlled trials. Cancer 2000; 89(7): 1611–25 Johansen HK, Gotzsche PC. Amphotericin B vs fluconazole for controlling fungal infections in neutropenic cancer patients (Cochrane review). Cochrane Database Syst Rev. 2000 (4): CD000239 Johansen HK, Gotzsche PC. Amphotericin B versus fluconazole for controlling fungal infections in neutropenic cancer patients (Cochrane Review). Cochrane Database Syst Rev. 2002 (2): CD000239 Hertenstein B, Kern WV, Schmeiser T, et al. Low incidence of invasive fungal infections after bone marrow transplantation in patients receiving amphotericin B inhalations during neutropenia [see comments]. Ann Hematol 1994; 68(1): 21–6 Erjavec Z, Woolthuis GM, de Vries-Hospers HG, et al. Tolerance and efficacy of amphotericin B inhalations for prevention of invasive pulmonary aspergillosis in haematological patients. Eur J Clin Microbiol Infect Dis 1997; 16(5): 364–8 Schwartz S, Behre G, Heinemann V, et al. Aerosolized amphotericin B inhalations as prophylaxis of invasive Aspergillus infections during prolonged neutropenia: results of a prospective randomized multicenter trial. Blood 1999; 93(11): 3654–61 Perfect JR, Klotman ME, Gilbert CC, et al. Prophylactic intravenous amphotericin B in neutropenic autologous bone marrow transplant recipients. J Infect Dis 1992; 165(5): 891–7 Wolff SN, Fay J, Stevens D, et al. Fluconazole vs low-dose amphotericin B for the prevention of fungal infections in patients undergoing bone marrow transplantation: a study of the North American Marrow Transplant Group. Bone Marrow Transplant 2000; 25(8): 853–9 Bodey GP, Anaissie EJ, Elting LS, et al. Antifungal prophylaxis during remission induction therapy for acute leukemia fluconazole versus intravenous amphotericin B. Cancer 1994; 73(8): 2099–106 Arning M, Scharf RE. Prevention of amphotericin-B-induced nephrotoxicity by loading with sodium chloride: a report of 1291 days of treatment with amphotericin B without renal failure. Klin Wochenschr 1989; 67(20): 1020–8 Karthaus M, Doellmann T, Klimasch T, et al. Intensive intravenous amphotericin B for prophylaxis of systemic fungal infections. Results of a prospective controlled pilot study in acute leukemia patients. Chemotherapy 2000; 46(4): 293–302 Böhme A, Hoelzer D. Primary antifungal prophylaxis with low-dose intravenous amphotericin B in hematological malignancies. Results of a pilot study. Onkologie 2000; 23: 145–50 BitMansour A, Brown JMY. Prophylactic administration of liposomal amphotericin B is superior to treatment in a murine model of invasive aspergillosis after hematopoietic cell transplantation. J Inf Dis 2002; 186: 134–7 Tollemar J, Ringden O, Andersson S, et al. Randomized double-blind study of liposomal amphotericin B (Ambisome) prophylaxis of invasive fungal infections in bone marrow transplant recipients. Bone Marrow Transplant 1993; 12(6): 577–82 Tollemar J, Ringden O, Andersson S, et al. Prophylactic use of liposomal amphotericin B (AmBisome) against fungal infections: a randomized trial in bone marrow transplant recipients. Transplant Proc 1993; 25 (1 Pt 2): 1495–7 Tollemar J, Hockerstedt K, Ericzon BG, et al. Fungal prophylaxis with AmBisome in liver and bone marrow transplant recipients: results of two randomized double-blind studies. Transplant Proc 1994; 26(3): 1833 Kelsey SM, Goldman JM, McCann S, et al. Liposomal amphotericin (AmBisome) in the prophylaxis of fungal infections in neutropenic patients: a randomised, double-blind, placebo-controlled study. Bone Marrow Transplant 1999; 23(2): 163–8 Lopez-Medrano F, Diaz-Pedroche C, Lumbreras C, et al. Usefulness of liposomal amphotericin B for the prophylaxis of fungal infection in solid organ transplant recipients [in Spanish]. Rev Esp Quimioter 2005 Mar; 18(1): 14–20 Mattiuzzi GN, Kantarjian H, Faderl S, et al. Amphotericin B lipid complex as prophylaxis of invasive fungal infections in patients with acute myelogenous leukemia and myelodysplastic syndrome undergoing induction chemotherapy. Cancer 2004 Feb 1; 100(3): 581–9 Corcoran TE, Venkataramanan R, Mihelc KM, et al. Aerosol deposition of lipid complex amphotericin-B (Abelcet) in lung transplant recipients. Am J Transplant 2006 Nov; 6(11): 2765–73 Jansen J, Akard LP, Wack MF, et al. Delayed ABLC prophylaxis after allogeneic stem-cell transplantation. Mycoses. 2006 Sep; 49(5): 397–404 Alexander BD, Dodds Ashley ES, Addison RM, et al. Non-comparative evaluation of the safety of aerosolized amphotericin B lipid complex in patients undergoing allogeneic hematopoietic stem cell transplantation. Transpl Infect Dis 2006 Mar; 8(1): 13–20 Timmers GJ, Zweegman S, Simoons-Smit AM, et al. Amphotericin B colloidal dispersion (Amphocil) vs fluconazole for the prevention of fungal infections in neutropenic patients: data of a prematurely stopped clinical trial. Bone Marrow Transplant 2000; 25(8): 879–84 Menichetti F, Del Favero A, Martino P, et al. Itraconazole oral solution as prophylaxis for fungal infections in neutropenic patients with hematologic malignancies: a randomized, placebo-controlled, double-blind, multicenter trial. GIMEMA Infection Program. Gruppo Italiano Malattie Ematologiche dell’ Adulto. Clin Infect Dis 1999; 28(2): 250–5 Boogaerts M, Maertens J, van Hoof A, et al. Itraconazole versus amphotericin B plus nystatin in the prophylaxis of fungal infections in neutropenic cancer patients. J Antimicrob Chemother 2001; 48(1): 97–103 Karthaus M, Cornely OA, Ullmann AJ. Itraconazole versus fluconazole for antifungal prophylaxis. Ann Intern Med 2004 Apr 6; 140(7): 579–80; author reply 81-2 Glasmacher A, Cornely O, Ullmann AJ, et al. An open-label randomized trial comparing itraconazole oral solution with fluconazole oral solution for primary prophylaxis of fungal infections in patients with haematological malignancy and profound neutropenia. J Antimicrob Chemother 2006 Feb; 57(2): 317–25 Oren I, Rowe JM, Sprecher H, et al. A prospective randomized trial of itraconazole vs fluconazole for the prevention of fungal infections in patients with acute leukemia and hematopoietic stem cell transplant recipients. Bone Marrow Transplant 2006 Jul; 38(2): 127–34 Morgenstern GR, Prentice AG, Prentice HG, et al. A randomized controlled trial of itraconazole versus fluconazole for the prevention of fungal infections in patients with haematological malignancies. UK Multicentre Antifungal Prophylaxis Study Group. Br J Haematol 1999; 105(4): 901–11 Glasmacher A, Molitor E, Hahn C, et al. Antifungal prophylaxis with itraconazole in neutropenic patients with acute leukaemia. Leukemia 1998; 12(9): 1338–43 Sharpe MD, Ghent C, Grant D, et al. Efficacy and safety of itraconazole prophylaxis for fungal infections after orthotopic liver transplantation: a prospective, randomized, double-blind study. Transplantation 2003 Sep 27; 76(6): 977–83 Cornely OA, Böhme A, Vehreschild JJ, et al. Primary antifungal prophylaxis during induction chemotherapy for acute myelogenous leukemia: voriconazole vs. placebo. Onkologie 2006; 29 Suppl. 3: P879 Husain S, Paterson DL, Studer S, et al. Voriconazole prophylaxis in lung transplant recipients. Am J Transplant 2006; 6(12): 3008–16 Cornely OA, Maertens J, Winston D, et al. Posaconazole vs standard azole therapy for prophylaxis of invasive fungal infections among high-risk neutropenic patients: results of a randomized, multicenter trial. Blood 2005; 106(11): 1844 Cornely OA, Maertens J, Winston D, et al. Posaconazole vs standard azoles as antifungal prophylaxis in neutropenic patients with acute myelogenous leukemia or myelodysplastic syndrome: impact on mortality. 45th Interscience Conference on Antimicrobial Agents and Chemotherapy; 2005 Dec 16–19; Washington DC Ullmann AJ, Lipton JH, Vesole DH, et al. Posaconazole vs fluconazole for prophylaxis of invasive fungal infections in allogeneic hematopoietic stem cell transplant recipients with graft-versus-host disease. 45th Interscience Conference on Antimicrobial Agents and Chemotherapy; 2005 Dec 16–19; Washington DC Mattiuzzi GN, Alvarado G, Giles FJ, et al. Open-label, randomized comparison of itraconazole versus caspofungin for prophylaxis in patients with hematologic malignancies. Antimicrob Agents Chemother 2006 Jan; 50(1): 143–7 van Burik JA, Ratanatharathorn V, Stepan DE, et al. Micafungin versus fluconazole for prophylaxis against invasive fungal infections during neutropenia in patients undergoing hematopoietic stem cell transplantation. Clin Infect Dis 2004 Nov 15; 39(10): 1407–16 Cornely OA, Ullmann AJ, Karthaus M. Choosing a study population for the evaluation of antifungal prophylaxis. Clin Infect Dis 2005 Jun 1; 40(11): 1699; author reply 1701 Offner F, Cordonnier C, Ljungman P, et al. Impact of previous aspergillosis on the outcome of bone marrow transplantation. Clin Infect Dis 1998 May; 26(5): 1098–103 Cordonnier C, Maury S, Pautas C, et al. Secondary antifungal prophylaxis with voriconazole to adhere to scheduled treatment in leukemic patients and stem cell transplant recipients. Bone Marrow Transplant 2004 May; 33(9): 943–8 Cornely OA, Böhme A, Reuter S, et al. Efficacy of secondary antifungal prophylaxis (SP) and risk factors for breakthrough infection (IFI) after pulmonary IFI in AML patients: a multinational case registry. 44th Interscience Conference on Antimicrobial Agents and Chemotherapy; 2004 Feb 10–11; Washington DC Schimpff SC, Greene WH, Young VM, et al. Infection prevention in acute nonlymphocytic leukemia: laminar air flow room reverse isolation with oral, nonabsorbable antibiotic prophylaxis. Ann Intern Med 1975; 82(3): 351–8 Bodey GP, Freireich EJ. Influence of high-efficiency particulate air filtration on mortality and fungal infection: a rebuttal. J Infect Dis 2006 Dec 1; 194(11): 1621–2 Eckmanns T, Rüden H, Gastmeier P. Reply to Bodey and Freireich. J Infect Dis 2006 Dec 1; 194(11): 1622–3 Eckmanns T, Ruden H, Gastmeier P. The influence of high-efficiency particulate air filtration on mortality and fungal infection among highly immunosuppressed patients: a systematic review. J Infect Dis 2006 May 15; 193(10): 1408–18